Suraksha Diagnostic Share Price: Target 2026–2030, Valuation and Risks

Suraksha Diagnostic share price today

The suraksha diagnostic share price question is really a question about how much an investor should pay for a regional pathology and imaging chain that is growing revenue in the low twenties but has not yet converted that growth into a matching rise in reported profit. Diagnostics is an appealing business in theory: tests repeat, referrals compound, and a trusted brand in a city is hard to displace. The tension here is that the market is already paying a software-like multiple for a hardware-heavy service network.

At the 10 September 2026 research cut-off, the closing price was ₹334.80, market capitalisation was about ₹1,743 crore and trailing EPS was ₹6.87. That works out to roughly 48.7 times trailing earnings and 7.1 times book value of ₹47.17 a share. The quote above moves after publication; every ratio and scenario input below stays fixed to that cut-off.

The share also sits within 2% of its 52-week high of ₹340.80 and roughly 47% above the 52-week low of ₹227.95. So this is not a neglected micro-cap being picked up cheaply. It is a stock that has already re-rated, and the analytical job is to decide what the earnings stream has to do from here to justify that.

What Suraksha Diagnostic actually does

Suraksha Diagnostic was founded in 1992 and is based in Kolkata. It runs diagnostic centres offering pathology and radiology, supported by home collection, on-site clinics and online consultation. It employs about 1,600 people. The service list is unusually broad for a company of this size, which is both the opportunity and the capital problem.

Service layer	Representative offering	What it requires	Economic characteristic
Core pathology	Microbiology, serology, haematology, clinical biochemistry, immunology	Accredited labs and sample logistics	High volume, repeat testing, price-competitive
Advanced genomics	NGS, FISH, karyotyping, QF-PCR, microarray, NIPT	Specialist equipment and reporting expertise	Higher realisation per test, thinner volume
Radiology and imaging	X-ray, MRI, CT, USG, DEXA, mammography, OPG	Heavy capital equipment per centre	Capital intensive and depreciation-heavy
Cardiology and neurology	ECG, echocardiogram, TMT, Holter, EEG, EMG, NCV	Machines plus reporting doctors	Adds throughput to centres already built
Endoscopy and clinics	Upper and lower GI endoscopy, colonoscopy, dental, physiotherapy, ENT, eye, fetal care	Clinical staff on site	Turns a lab into a care destination
Home and digital	Home collection, home doctor visits, online consultation, curated packages	Field phlebotomy and scheduling	Widens catchment without new centres

The strategic logic is that a patient who comes in for a routine blood panel can be served again for imaging, a specialist consultation or an annual package, and that each additional service raises utilisation of a centre whose rent, machines and staff are already paid for. That is a genuine operating-leverage story. It only works if footfall per centre keeps rising; if it does not, the same breadth becomes fixed cost with nothing running through it.

The revenue and profit record through FY26

The annual rows below come from Yahoo Finance, where each row is labelled by the calendar year in which the March financial year ended; the sourcing is set out in full at the end.

Financial year	Revenue	Net profit	Year-on-year reading
FY24	Not captured	₹24 Cr	Base year for the profit series
FY25	₹252 Cr	₹32 Cr	Profit up about a third
FY26	₹310 Cr	₹32 Cr	Revenue up about 23%, profit flat
TTM to the cut-off	₹325 Cr	About ₹36 Cr implied	Trailing period, not a reported year

The FY26 line is the one that matters. Revenue rose from ₹252 crore to ₹310 crore, an increase of roughly 23%, while net profit stayed at ₹32 crore. Growth of that size producing no incremental profit means the cost of adding it, in staff, rent, equipment and depreciation, absorbed the entire gross benefit.

The trailing twelve months look better. TTM revenue is ₹325 crore and the trailing EPS of ₹6.87 across about 5.21 crore shares implies trailing profit near ₹36 crore, which cross-checks with the reported 11% net profit margin on ₹325 crore. Yahoo’s own year-on-year readings at the cut-off show revenue growth of 20.7% and earnings growth of 38.9%. That is a recovery in profitability against a flat FY26, but it is one trailing period, not an established trend.

Margins, depreciation and the balance sheet

Diagnostics chains report a wide gap between EBITDA and operating profit, because MRI machines, CT scanners and fitted-out centres depreciate. Suraksha is a clean example, and the gap is the single most useful thing in its P&L.

Measure	Reading at 10 September 2026	Why it matters
TTM revenue	₹325 Cr	The base for every margin below
EBITDA	₹107 Cr	About 32.9% of revenue, a healthy centre-level economics signal
Operating margin	21.8%	The 11-point gap to EBITDA is largely depreciation and amortisation
Net profit margin	11%	Interest and tax take roughly half of operating profit
Total debt	₹130 Cr	Funded expansion, not a distressed balance sheet
Cash and equivalents	₹26 Cr	Implies net debt of about ₹104 Cr
Debt to equity	53.5%	Meaningful leverage for a company of this size
ROCE	16.97%	Screener-derived reading dated 5 August 2026
Employees	1,600	A people-heavy as well as machine-heavy model

Two readings follow. The constructive one is that a 32.9% EBITDA margin says the centres themselves work: tests are priced above their marginal cost and utilisation is reasonable. The cautious one is that ROCE of 16.97% against debt to equity of 53.5% means the return on the whole capital base, including borrowed money, is not far above what that capital costs. A company earning 17% on capital while paying interest on ₹130 crore of debt has less margin for error than the EBITDA line alone suggests. If you want the arithmetic behind that leverage ratio, the debt-to-equity ratio guide sets it out step by step.

Growth rates: what the five-year record shows

The Screener-derived readings dated 5 August 2026 put the five-year sales CAGR at 17.26% and the five-year profit CAGR at 31.68%. Those are strong numbers, and they explain why the market is willing to pay a high multiple. They also need moderating before they are projected forward.

Profit compounding at nearly twice the rate of sales over five years is arithmetic that depends on the starting point. A company that begins with thin margins can double its profit growth rate relative to revenue for a few years simply by filling capacity, and then cannot do it again. The FY26 result, where 23% revenue growth produced no profit growth at all, is exactly what that exhaustion looks like when a new expansion cycle begins. Any honest forward model has to sit closer to the sales CAGR than to the profit CAGR.

Valuation at the 10 September 2026 cut-off

Valuation measure	10 September 2026 reading	Interpretation
Closing price	₹334.80	Fixed research input, not a live figure
Market capitalisation	₹1,743 Cr	Micro-cap, so liquidity and execution risk matter
Shares outstanding	About 5.21 crore	Small float relative to larger listed peers
Trailing EPS	₹6.87	Trailing twelve months to the cut-off
Price to earnings	48.73×	Price divided by trailing EPS
Book value per share	₹47.17	Implies price to book of 7.1×
ROCE	16.97%	Below what a 49-times multiple usually implies
Dividend yield	0.15%	The case rests on reinvestment, not income
52-week range	₹227.95 to ₹340.80	Price sits 1.76% below the high
Promoter holding	61.97%	Founding family retains clear control

Forty-nine times earnings and seven times book is a premium rating for a business earning 17% on capital. It is defensible only if profit growth reaccelerates from the FY26 pause and stays high for several years. Readers who want the mechanics of that multiple can work through the P/E ratio formula guide; the comparison that matters here is against other listed healthcare operators such as Apollo Hospitals, where scale and brand support a different cost of capital, and against pharma names such as Abbott India, where returns on capital are structurally higher.

A 34% re-rating in five weeks, on unchanged earnings

The re-rating is recent and it has been sharp. The Screener-derived readings dated 5 August 2026 showed a market capitalisation of about ₹1,300 crore, a 52-week high of ₹327.90 and a price sitting 23.9% below that high. Five weeks later, market capitalisation was ₹1,743 crore, the 52-week high had been reset to ₹340.80 and the price was 1.76% below it.

That is roughly a 34% increase in market value in about five weeks, against a 52-week low of ₹227.95 that did not move. Nothing in the captured financial data changed by a third over that period. The revenue and profit rows are annual, the return on capital is unchanged at 16.97%, and no new statement table was captured between the two dates. The move therefore reflects a change in what the market is willing to pay for the same earnings, not a change in the earnings themselves.

That distinction is the whole valuation argument. Buying a business after the multiple has expanded means two things now have to go right rather than one: the earnings have to grow, and the market has to keep granting the higher multiple while they do. The scenario framework below separates those two variables deliberately so that each can be judged on its own.

Valuation framework: growth and multiple, separated

The scenario model starts with TTM EPS of ₹6.87. For each year it applies EPS_TTM × (1 + growth)^(year − 2026 + 112/365) × exit P/E, then rounds the result to the nearest ₹5. The 112/365 factor represents the fraction of the first forecast year remaining from 10 September to 31 December. Dividends are excluded, which at a 0.15% yield changes very little.

Scenario	Annual EPS growth	Exit P/E	Business interpretation
Bear	8%	25×	Expansion keeps absorbing profit as it did in FY26, and the market re-rates a leveraged mid-teens-ROCE operator down to a services multiple
Base	15%	40×	Centre utilisation improves, depreciation is absorbed, profit compounds a little slower than the five-year sales CAGR of 17.26% rather than at the historical profit rate, and the rating settles slightly below today’s
Bull	22%	55×	Genomics and imaging mix lifts realisation per patient, operating leverage returns, and the market keeps paying a premium for a scarce listed diagnostics asset

Two constraints shaped these numbers. The exit multiples run from well below today’s 48.73 up to only modestly above it, because assuming both flawless execution and permanent multiple expansion would just restate the current enthusiasm as a forecast. And the growth rates are anchored to the five-year sales CAGR of 17.26% rather than to the profit CAGR: two of the three sit below it, the bear case at 8% well below and the base case at 15% just under, and even the bull case at 22% stops far short of the five-year profit CAGR of 31.68%, because the FY26 flat-profit year is direct evidence that the historical profit rate is not repeatable on demand. The method behind this approach is described in full in how to value a stock.

Suraksha Diagnostic share price target 2026 to 2030

The grid is generated purely from the trailing EPS, the three growth rates and the three exit multiples disclosed above, with the partial-year convention applied to 2026. It does not model a fresh equity issue, an acquisition of another lab network, a change in the debt load, an exceptional item, a regulatory change to test pricing, or any shift in the share count. It is also not probability-weighted: the three paths are illustrations of what different assumptions produce, not forecasts with odds attached. Anyone using the framework after the next set of results should re-run it with the updated trailing EPS rather than carrying these inputs forward.

Risks that can break the thesis

The first risk is the starting multiple itself. At 48.73 times trailing earnings, a stock can deliver several years of genuine profit growth and still produce a poor return if the rating drifts back toward the market average. This is the dominant risk in the name, and it is entirely independent of how well the company operates.

The second is capital intensity. Imaging equipment has to be replaced, centres have to be fitted out, and the 11-point gap between the 32.9% EBITDA margin and the 21.8% operating margin is the ongoing cost of that. With ₹130 crore of debt against ₹26 crore of cash and debt to equity of 53.5%, another aggressive expansion cycle would either raise leverage further or require equity.

The third is regional concentration and competition. The company is based in Kolkata, and a diagnostics network’s brand equity is local. National chains, hospital-owned labs and low-cost online aggregators all compete for the same tests, and pathology pricing is not protected. Add the FY26 evidence that revenue growth passed straight through to costs, and the possibility that growth continues without profit following is a real one rather than a theoretical one.

Finally, the data available on this name is thinner than usual. There is no captured quarterly profit line and no captured Screener financial history, so the FY26 flat-profit year cannot be decomposed into the quarters that caused it. That is a reason for caution about the precision of any conclusion drawn here, including this one.

What would change the picture

The case strengthens if profit growth reappears alongside revenue growth for several consecutive periods, if the operating margin rises toward the EBITDA margin as existing centres absorb their depreciation, and if net debt falls while the network still expands. A rising share of genomics and imaging in the mix would help, because realisation per patient is higher there than in routine pathology. ROCE moving from 17% toward the low twenties without added leverage would be the single clearest signal that the capital already deployed is working.

It weakens if another year passes with strong revenue growth and static profit, if debt rises to fund the next expansion, if the EBITDA margin slips as competition presses test pricing, or if the recent re-rating unwinds as quickly as it arrived. A dilutive equity raise at a lower multiple would change the per-share arithmetic for every scenario above.

Monitoring scorecard

Question	Constructive evidence	Warning sign
Is revenue growth reaching profit?	Profit grows at least as fast as sales	Another FY26-style year of flat profit on higher revenue
Is depreciation being absorbed?	Operating margin climbs toward the EBITDA margin	The 11-point gap widens as new centres open
Is leverage under control?	Net debt falls while the network still expands	Debt to equity rises above the current 53.5%
Is the mix improving?	Genomics and imaging raise realisation per patient	Growth comes only from low-priced routine panels
Is capital earning enough?	ROCE moves above the high teens	ROCE falls while the asset base grows
Is the rating supported?	Earnings growth catches up with the multiple	Multiple holds while earnings stall

FAQ

What is Suraksha Diagnostic’s share price target for 2026?

The 2026 line in the scenario grid covers only the fraction of the year remaining from the 10 September 2026 cut-off, applied through the 112/365 convention explained above. It is produced from trailing EPS of ₹6.87 and the three exit multiples disclosed in the framework section. It is a range of arithmetic outcomes under stated assumptions, not a prediction.

What is Suraksha Diagnostic’s share price target for 2030?

The 2030 line compounds the same trailing EPS forward at 8%, 15% or 22% a year and applies the corresponding exit multiple. Four years of compounding makes the 2030 spread very wide, because small differences in the growth rate and the multiple both magnify over time. Treat the width of that range as the honest message rather than any single figure inside it.

What does Suraksha Diagnostic do?

It operates diagnostic centres in India providing pathology and radiology services, including microbiology, haematology, biochemistry, immunology and advanced genomics such as NGS, FISH and NIPT, alongside MRI, CT, ultrasound, mammography and DEXA imaging. It also runs cardiology, neurology, endoscopy and specialty clinic services, home sample collection, home doctor visits and online consultation. The company was founded in 1992 and is based in Kolkata.

Who are the promoters of Suraksha Diagnostic?

Promoter holding was 61.97% at the 10 September 2026 cut-off, which means the founding group retains clear control of the company. A stake of that size limits the free float and can make the share price more volatile on modest volumes. Current shareholding is disclosed in the company’s exchange filings, which are linked in the sources section.

Is Suraksha Diagnostic listed on the NSE and BSE?

Every figure in this article is tied to the NSE line, symbol SURAKSHA, and the quote widget at the top of the page tracks SURAKSHA.NS. The captured data set records that NSE listing only, so this article does not assert a second exchange line one way or the other. If the exchange matters for how you intend to deal in the share, confirm it on the NSE quote page linked in the sources below and on the BSE’s own quote page before relying on either.

Where can I check the Suraksha Diagnostic share price today?

The quote widget at the top of this page carries the live NSE price for SURAKSHA.NS. The NSE quote page linked below shows the same price alongside corporate filings, delivery data and the 52-week range, and Screener.in carries the ratio history. Everything else in this article stays fixed to the 10 September 2026 close of ₹334.80.

Related research

• Apollo Hospitals share price target
• Abbott India share price target
• How to value a stock: the method behind every target on this site
• P/E ratio formula, meaning and calculation
• Debt-to-equity ratio: formula and how to use it

Sources and methodology

• Suraksha Diagnostic on Screener.in
• Suraksha Diagnostic quote and filings on NSE
• Suraksha Diagnostic company website

All market figures in this article were captured after the completed 10 September 2026 session. The closing price of ₹334.80, the 52-week range, market capitalisation, trailing EPS, book value, price to book, dividend yield, debt, cash, EBITDA, margins, share count, employee count, promoter holding and the business description came from Yahoo Finance. The five-year sales and profit CAGRs and the ROCE of 16.97% came from Screener-derived readings dated 5 August 2026, along with the earlier market capitalisation and 52-week high used in the re-rating comparison. No Screener financial statement table was captured for this company, which is why the annual revenue and profit rows are sourced from Yahoo, where each row is labelled by the calendar year in which the March financial year ended. The only quarterly datum captured is a single Yahoo row, 4Q2025 revenue of ₹78 crore, with no matching quarterly profit line, which is why no quarter-by-quarter section appears and the FY26 flat-profit year is not decomposed here. Where a figure was not available it is marked as such in the tables above rather than estimated.

Analytical judgment begins after those figures. The reading of the FY26 flat-profit year, the interpretation of the gap between the EBITDA and operating margins, the assessment of leverage against ROCE, the view that the recent move was a re-rating rather than an earnings event, and the choice of growth rates and exit multiples in the scenario framework are all interpretation, not reported data. The scenario engine uses only the formula and partial-year convention disclosed above; the live quote does not recalculate it.

---

This article is research and education, not personalised investment advice or a recommendation to transact. Gale is not a SEBI-registered investment adviser. The scenarios are illustrations, not guarantees. Verify current exchange filings, liquidity, corporate actions and suitability, and consult a registered adviser before acting.